{
“@context”: “https://schema.org”,
“@type”: “Article”,
“mainEntityOfPage”: {
“@type”: “WebPage”,
“@id”: “https://www.clinicalstudies.in/korean-language-consent-and-document-localization”
},
“@id”: “https://www.clinicalstudies.in/korean-language-consent-and-document-localization”,
“headline”: “SOP for Korean Language Consent and Document Localization”,
“name”: “SOP for Korean Language Consent and Document Localization”,
“description”: “Comprehensive SOP describing sponsor and investigator responsibilities for preparing Korean-language informed consent forms and ensuring accurate localization of essential trial documents in compliance with MFDS and Korean GCP.”,
“keywords”: “Korean consent SOP, SOP for document localization Korea, SOP for clinical trial translations Korea, SOP for informed consent Korean language, SOP for essential documents Korea, SOP for ICF Korean translation SOP, SOP for subject-facing documents Korea, SOP for translation vendor SOP Korea, SOP for patient safety documents Korea, SOP for ethics submissions Korea, SOP for BASEC equivalent Korea, SOP for Korean trial governance, SOP for investigator responsibilities Korean documentation, SOP for sponsor translation oversight Korea, SOP for regulatory submissions Korea, SOP for eConsent Korean requirements, SOP for cultural adaptation of trial materials Korea, SOP for patient comprehension SOP Korea, SOP for bilingual documentation Korea, SOP for audit readiness translation Korea, SOP for archiving translated records Korea, SOP for data integrity in translations Korea, SOP for GCP compliance Korean documentation, SOP for CRO translation responsibilities Korea, SOP for inspection readiness Korean trials”,
“articleSection”: “Standard Operating Procedure”,
“datePublished”: “2025-08-28”,
“dateModified”: “2025-08-28”,
“author”: { “@type”: “Organization”, “name”: “Clinicalstudies.in” },
“publisher”: {
“@type”: “Organization”,
“name”: “Clinicalstudies.in”,
“logo”: { “@type”: “ImageObject”, “url”: “https://www.clinicalstudies.in/logo.png” }
}
}

Korean Language Consent and Document Localization SOP

Purpose

This SOP defines requirements for preparing informed consent forms (ICFs) and essential documents in the Korean language, ensuring cultural, linguistic, and regulatory compliance. It ensures participant comprehension, ethical compliance, and alignment with MFDS and Korean GCP standards.

Scope

This SOP applies to all clinical trials conducted in South Korea where subject-facing documents and essential regulatory documents require Korean language localization. It covers translation, back-translation, certification, cultural adaptation, ethics submissions, and archiving of localized records.

Responsibilities

• Sponsor: Ensures availability of ICFs and subject-facing materials in Korean, oversees translation processes, and verifies certification.
• Principal Investigator (PI): Ensures participants understand the content of the ICF and maintains localized versions in the ISF.
• Regulatory Affairs (RA): Submits localized documents to MFDS and ethics committees.
• Translation Vendor: Provides certified translations and back-translations of documents.
• Quality Assurance (QA): Audits translation and localization processes to ensure compliance with KGCP.

Accountability

The Sponsor’s Head of Clinical Operations is accountable for ensuring localized document availability. The PI is accountable for confirming comprehension during the consent process.

Procedure

1. Identification of Documents Requiring Localization

1. Prepare a list of documents needing translation (ICFs, PIS, subject leaflets, safety reports).
2. Document requirements in Translation Tracker (Annexure-1).

2. Translation and Back-Translation

1. Engage certified medical translators for Korean translation.
2. Perform back-translation into English to verify accuracy.
3. Retain Certificate of Translation Accuracy in TMF.

3. Ethics Submission

1. Submit localized ICFs and patient materials to ethics committees and MFDS.
2. Maintain acknowledgment letters in Submission Log (Annexure-2).

4. Consent Process

1. Ensure that PIs or delegated staff explain the consent form to participants in Korean.
2. Confirm comprehension by asking subjects to summarize key points.

5. Archiving

1. Maintain localized documents in ISF and TMF for at least 10 years post-study.
2. Ensure availability for inspections and audits.

Abbreviations

• MFDS: Ministry of Food and Drug Safety
• KGCP: Korean Good Clinical Practice
• ICF: Informed Consent Form
• PIS: Patient Information Sheet
• ISF: Investigator Site File
• TMF: Trial Master File
• RA: Regulatory Affairs
• QA: Quality Assurance
• PI: Principal Investigator

Documents

1. Translation Tracker (Annexure-1)
2. Submission Log (Annexure-2)
3. Certificate of Translation Accuracy (Annexure-3)

References

• MFDS — Ministry of Food and Drug Safety
• ICH E6(R2) Good Clinical Practice
• WHO Clinical Trials Guidelines

Version: 1.0

Approval

Annexures

Annexure-1: Translation Tracker

Annexure-2: Submission Log

Annexure-3: Certificate of Translation Accuracy

Revision History

For more SOPs visit: Pharma SOP.

{
“@context”: “https://schema.org”,
“@type”: “Article”,
“mainEntityOfPage”: {
“@type”: “WebPage”,
“@id”: “https://www.clinicalstudies.in/mfds-submissions-and-korean-gcp-alignment”
},
“@id”: “https://www.clinicalstudies.in/mfds-submissions-and-korean-gcp-alignment”,
“headline”: “SOP for MFDS Submissions and Korean GCP Alignment”,
“name”: “SOP for MFDS Submissions and Korean GCP Alignment”,
“description”: “Comprehensive SOP describing sponsor, investigator, and regulatory responsibilities for clinical trial submissions to the Ministry of Food and Drug Safety (MFDS) in South Korea, aligned with Korean GCP.”,
“keywords”: “MFDS submission SOP, Korean GCP alignment SOP, SOP for regulatory submissions South Korea, SOP for CTA South Korea, SOP for clinical trial approvals Korea, SOP for investigator responsibilities MFDS, SOP for sponsor obligations MFDS submissions, SOP for CRO regulatory submissions Korea, SOP for safety reporting MFDS Korea, SOP for regulatory compliance South Korea, SOP for ethics submissions Korea, SOP for trial conduct MFDS compliance, SOP for DSUR submission MFDS, SOP for ICSR reporting Korea, SOP for inspection readiness MFDS, SOP for GCP compliance Korea, SOP for clinical trial dossier submission Korea, SOP for PV reporting Korea, SOP for Korean clinical trial governance, SOP for protocol amendments Korea, SOP for documentation archiving Korea, SOP for sponsor regulatory strategy Korea, SOP for investigator CTA compliance Korea, SOP for RA responsibilities Korea, SOP for QA oversight Korea, SOP for Korean regulatory timelines SOP”,
“articleSection”: “Standard Operating Procedure”,
“datePublished”: “2025-08-28”,
“dateModified”: “2025-08-28”,
“author”: { “@type”: “Organization”, “name”: “Clinicalstudies.in” },
“publisher”: {
“@type”: “Organization”,
“name”: “Clinicalstudies.in”,
“logo”: { “@type”: “ImageObject”, “url”: “https://www.clinicalstudies.in/logo.png” }
}
}

MFDS Submissions and Korean GCP Alignment SOP

Purpose

The purpose of this SOP is to define processes for submitting clinical trial applications and related documentation to the Ministry of Food and Drug Safety (MFDS) in South Korea, while ensuring full alignment with Korean Good Clinical Practice (KGCP). It ensures that sponsor and investigator obligations are fulfilled in compliance with local regulations and international GCP standards.

Scope

This SOP applies to all clinical trials conducted in South Korea that require MFDS authorization. It covers clinical trial applications (CTA), amendments, safety reporting, DSURs, ICSRs, and archiving. It applies to sponsors, CROs, investigators, regulatory affairs teams, and quality assurance staff engaged in clinical research.

Responsibilities

• Sponsor: Prepares and submits CTA dossier, oversees communications with MFDS, and ensures compliance with KGCP.
• Regulatory Affairs (RA): Compiles required documents, submits applications, and maintains submission logs.
• Principal Investigator (PI): Provides site-level documentation and ensures compliance with approved protocols.
• CRO: Assists with dossier preparation, submissions, and communications with MFDS, as delegated.
• Quality Assurance (QA): Reviews submission packages and ensures inspection readiness.

Accountability

The Sponsor’s Head of Regulatory Affairs is accountable for timely and complete MFDS submissions. The PI is accountable for site-level compliance with KGCP and MFDS requirements.

Procedure

1. Preparation of CTA Dossier

1. Compile dossier including protocol, Investigator’s Brochure (IB), Informed Consent Form (ICF), Investigator CVs, GMP certificates, and relevant preclinical/CMC data.
2. Ensure translations into Korean where required.
3. Complete Submission Checklist (Annexure-1).

2. Submission to MFDS

1. Submit application electronically to MFDS via official portal.
2. Maintain record of submission reference number in Submission Log (Annexure-2).

3. Ethics Committee (EC) Coordination

1. Submit documents simultaneously to Institutional Review Boards (IRBs) for approval.
2. Ensure IRB approval is aligned with MFDS requirements before trial initiation.

4. Safety Reporting

1. Report SAEs and SUSARs in accordance with MFDS timelines.
2. Submit ICSRs electronically to MFDS pharmacovigilance systems.
3. Prepare annual DSUR and submit within 60 days of data lock point.

5. Amendments

1. Prepare substantial amendment packages including revised protocol, IB, or ICF.
2. Submit to MFDS and IRB for approval prior to implementation.

6. Documentation and Archiving

1. Maintain TMF and ISF per KGCP requirements.
2. Archive documents for a minimum of 10 years post-trial completion.

Abbreviations

• MFDS: Ministry of Food and Drug Safety
• KGCP: Korean Good Clinical Practice
• CTA: Clinical Trial Application
• PI: Principal Investigator
• RA: Regulatory Affairs
• CRO: Contract Research Organization
• QA: Quality Assurance
• IB: Investigator’s Brochure
• ICF: Informed Consent Form
• DSUR: Development Safety Update Report
• ICSR: Individual Case Safety Report
• TMF: Trial Master File
• ISF: Investigator Site File

Documents

1. Submission Checklist (Annexure-1)
2. Submission Log (Annexure-2)
3. Safety Reporting Log (Annexure-3)

References

• MFDS — Ministry of Food and Drug Safety
• ICH E6(R2) Good Clinical Practice
• WHO Clinical Trials Guidelines

Version: 1.0

Approval

Annexures

Annexure-1: Submission Checklist

Annexure-2: Submission Log

Annexure-3: Safety Reporting Log

Revision History

For more SOPs visit: Pharma SOP.